Pacira Biosciences (NASDAQ:PCRX) posted its earnings results on Thursday. The company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.13 by $0.35, Briefing.com reports. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.62%. The business had revenue of $104.69 million for the quarter, compared to the consensus estimate of $104.88 million. During the same period last year, the company earned $0.31 EPS. The firm’s revenue was up 25.5% compared to the same quarter last year.
Shares of NASDAQ PCRX traded up $1.40 during midday trading on Friday, reaching $44.02. The stock had a trading volume of 711,200 shares, compared to its average volume of 631,161. The company’s 50 day moving average price is $39.20 and its 200 day moving average price is $41.12. The company has a debt-to-equity ratio of 0.99, a quick ratio of 4.12 and a current ratio of 4.75. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of 151.79, a price-to-earnings-growth ratio of 1.96 and a beta of 1.13. Pacira Biosciences has a twelve month low of $34.64 and a twelve month high of $50.90.
A number of brokerages have recently issued reports on PCRX. Stifel Nicolaus set a $42.00 price target on shares of Pacira Biosciences and gave the stock a “hold” rating in a research report on Friday, August 9th. BTIG Research began coverage on shares of Pacira Biosciences in a research report on Wednesday. They issued a “buy” rating and a $56.00 price target on the stock. Jefferies Financial Group set a $60.00 price target on shares of Pacira Biosciences and gave the stock a “buy” rating in a research report on Tuesday, October 8th. BidaskClub upgraded shares of Pacira Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Barclays boosted their price target on shares of Pacira Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $52.55.
In related news, CEO David M. Stack sold 12,849 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $39.15, for a total value of $503,038.35. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Kristen Marie Williams sold 6,252 shares of the business’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $39.49, for a total transaction of $246,891.48. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by insiders.
About Pacira Biosciences
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
See Also: What is the NASDAQ?
Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.